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AbstrACt
Introduction Intravenous thrombolysis (IVT) with 
recombinant tissue plasminogen activator (rt- PA) is the 
only approved pharmacological reperfusion therapy for 
acute ischaemic stroke. Despite population benefit, IVT 
is not equally effective in all patients, nor is it without 
significant risk. Uncertain treatment outcome prediction 
complicates patient treatment selection. This study 
will develop and validate predictive algorithms for IVT 
response, using clinical, radiological and blood- based 
biomarker measures. A secondary objective is to develop 
predictive algorithms for endovascular thrombectomy 
(EVT), which has been proven as an effective reperfusion 
therapy since study inception.
Methods and analysis The Targeting Optimal 
Thrombolysis Outcomes Study is a multicenter prospective 
cohort study of ischaemic stroke patients treated at 
participating Australian Stroke Centres with IVT and/or 
EVT. Patients undergo neuroimaging using multimodal 
CT or MRI at baseline with repeat neuroimaging 24 hours 
post- treatment. Baseline and follow- up blood samples are 
provided for research use. The primary outcome is good 
functional outcome at 90 days poststroke, defined as a 
modified Rankin Scale (mRS) Score of 0–2. Secondary 
outcomes are reperfusion, recanalisation, infarct core 
growth, change in stroke severity, poor functional outcome, 
excellent functional outcome and ordinal mRS at 90 days. 
Primary predictive models will be developed and validated 
in patients treated only with rt- PA. Models will be built 
using regression methods and include clinical variables, 
radiological measures from multimodal neuroimaging and 
blood- based biomarkers measured by mass spectrometry. 
Predictive accuracy will be quantified using c- statistics 
and R2. In secondary analyses, models will be developed 
in patients treated using EVT, with or without prior IVT, 
reflecting practice changes since original study design.
Ethics and dissemination Patients, or relatives when 
patients could not consent, provide written informed 
consent to participate. This study received approval from 
the Hunter New England Local Health District Human 
Research Ethics Committee (reference 14/10/15/4.02). 
Findings will be disseminated via peer- reviewed 
publications and conference presentations.
IntroduCtIon
The emergence of reperfusion therapy in acute 
ischaemic stroke with the collection of large 
and well- characterised patient data sets and 
the concurrent application of advanced brain 
imaging and ‘omics’ technologies provide an 
opportunity to develop a precision medicine 
approach to acute stroke care. Currently, when 
strengths and limitations of this study
 ► A strength of this study is prospective patient re-
cruitment by multiple Australian Stroke Centres.
 ► Predictive models will incorporate prognostic mea-
sures captured using advanced neuroimaging, 
which are increasingly used in reperfusion treat-
ment decisions.
 ► The analysis of blood samples using mass spectrom-
etry has the potential to identify novel biomarkers 
of intravenous thrombolysis (IVT) and endovascular 
thrombectomy (EVT) response.
 ► Statistical analyses are prespecified and the planned 
sample size provides adequate power to predict out-
comes with good precision.
 ► Because separate predictive models will be devel-
oped according to reperfusion therapy type (IVT, EVT 
or IVT+EVT), individual predictive models may not 
generalise to patients treated receiving alternate 
reperfusion therapies.
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facing difficult ‘benefit vs risk’ decisions, clinicians extrap-
olate summary estimates of treatment effectiveness or risk 
derived from clinical trial populations to the individual 
patient, who may or may not share trial patient character-
istics. The greater understanding of pathophysiology and 
endophenotypes afforded by advanced brain imaging, 
along with measurement of previously unrecognised factors 
influencing treatment responsiveness and risk of harm, 
provide the opportunity to move towards a new paradigm 
of precision stroke medicine.
Intravenous thrombolysis (IVT) with recombinant tissue 
plasminogen activator (rt- PA) within a therapeutic window 
of 4.5 hours (or up to 9 hours guided by multimodal imaging) 
is the only approved pharmacological reperfusion therapy 
for acute ischaemic stroke. Treatment of ischaemic stroke 
patients with rt- PA promotes clot lysis by accelerating the 
catalytic conversion of plasminogen to plasmin, a protease 
that dissolves fibrin. In randomised trials and observational 
studies, patients receiving timely rt- PA treatment demon-
strate higher recanalisation rates and more favourable 
clinical outcomes than patients not receiving reperfusion 
therapy.1–4 Despite the proven effectiveness of endovascular 
thrombectomy (EVT) for ischaemic strokes caused by prox-
imal large artery occlusion in the anterior circulation, rt- PA 
therapy remains first- line treatment for patients with and 
without a proximal anterior occlusion, or who present to 
a hospital where thrombectomy is not available, even if the 
patient is later transferred to a comprehensive stroke centre 
(CSC) for EVT (‘drip and ship’).
While the population benefit of rt- PA therapy is clear, 
thrombolysis is not equally effective in all ischaemic stroke 
patients, nor is it without significant risk. Among eligible 
patients treated within 4.5 hours of symptom onset, only 
about 35%–50% are alive and independent at 3 months 
poststroke,2–8 while 2%–10% (depending on definition) 
develop symptomatic intracranial haemorrhage (sICH), 
increasing the risk of early death.3 8 The treatment response 
for a given patient cannot be accurately predicted before 
treatment initiation, making patient selection challenging. 
Although some predictive factors have been identified, 
their prognostic value differs between patients, due to the 
presence of various individual and interacting factors. For 
example, treatment benefit is known to be time dependent, 
with shorter onset to treatment (OTT) times associated 
with higher rates of favourable outcome and reduced risk 
of sICH.9–11 However, the absolute benefit of reduced OTT 
time varies between patients, due to differences in collat-
eral circulation and salvageable brain volume.12 Thus, IVT 
therapy in delayed time windows can benefit some patients 
with larger volumes of mismatch between ischaemic 
penumbra and core, but has minimal benefit in patients 
with lower volumes of salvageable brain or large established 
infarcts.4 6 13
High individual variation in rt- PA response has motivated 
the development of scoring algorithms to predict individual 
patients’ thrombolysis response using baseline characteris-
tics. For a given patient, such scores aim to predict whether 
potential benefit of treatment outweighs the risk, thus 
informing treatment decisions. Various prediction models 
have been proposed,14–24 although none are routinely used 
in clinical care. Previously models were developed during 
the period 2006–2013 and included simple prognostic 
factors measured during routine clinical/laboratory exam-
inations—for example, age, blood glucose, stroke severity, 
OTT time and blood pressure—and/or basic neuroimaging, 
such as early infarct or dense artery signs visualised using 
non- contrast CT. However, recent randomised trials6 25–28 
demonstrate the central role of advanced neuroimaging 
modalities such as CT perfusion (CTP), CT angiography 
(CTA), diffusion- weighted MRI and MRI- fluid- attenuated 
inversion recovery in guiding ischaemic stroke patient 
selection for acute stroke therapy. In broader healthcare, 
there is also emerging interest in precision medicine for 
tailoring treatment decisions for individual patients using 
their genetic and/or molecular profiles.
The Targeting Optimal Thrombolysis Outcomes Study 
was designed to develop clinical decision rules for predicting 
patient outcomes following rt- PA therapy, using a combina-
tion of clinical, basic radiological, advanced radiological 
and blood- based biomarker measures. Decision rules will be 
developed in a prospective cohort of Australian ischaemic 
stroke patients treated with rt- PA. A unique component of 
the study is large- scale screening for blood- based protein 
biomarkers for rt- PA response using mass spectrometry. 
This study was funded by the Australian National Health 
and Medical Research Council (NHMRC: APP1085550) 
and is part of the portfolio of studies being conducted by 
the International Stroke Genetics Consortium (https:// 
strokegenetics. org/) assessing acute endophenotypes and 
predictors of acute ischaemic stroke outcome.
study objectives
Primary objective
The primary objective of this study is to develop and inter-
nally and externally validate prediction models for treat-
ment outcomes following rt- PA therapy in patients with 
acute ischaemic stroke, using clinical, radiological and 
blood- based biomarker variables.
Secondary objective
A secondary objective is to identify individual blood- 
based protein biomarkers associated with rt- PA treatment 
response, as potential candidates for diagnostic tests or 
adjunct therapies. An additional secondary objective is to 
identify clinical, radiological and biomarker predictors of 
treatment outcome in ischaemic stroke patients under-
going EVT, with or without prior rt- PA therapy.
MEthods And AnAlysIs
The design, conduct and reporting of this study will 
adhere to the Strengthening the Reporting of Obser-
vational Studies in Epidemiology29 and Transparent 
Reporting of a multivariable prediction model for Indi-
vidual Prognosis or Diagnosis30 checklists.
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Participants
Eligible patients will be ischaemic stroke patients aged 
≥18 years with clinicoradiological evidence of acute 
brain ischemia fulfilling standard eligibility criteria for 
IVT and/or EVT, who present to a participating Austra-
lian CSC or Primary Stroke Centre (PSC) from January 
2015 to December 2020. The cohort will include eligible 
patients who have multimodal imaging using either CT 
or MRI at the baseline evaluation (ie, including angi-
ography and perfusion imaging), with no evidence of 
intracranial haemorrhage, stroke mimic or other non- 
stroke pathology, and who are subsequently treated with 
reperfusion therapies. The principal study objective is to 
develop prediction models in patients treated with rt- PA. 
However, since study inception, EVT has been proven as 
an effective first- line or adjunct therapy for patients with 
proximal large artery occlusions presenting at, or trans-
ferred to, an EVT- capable stroke centre. Eligibility criteria 
were thus updated to include patients treated with EVT, 
to facilitate additional, exploratory assessment of prog-
nostic factors for EVT response. Patients with an absolute 
contraindication for reperfusion therapy, or for whom 
baseline or follow- up advanced CT and/or MRI is not 
performed, will be excluded from the study.
Patients will be asked to provide written informed 
consent for their clinical, imaging and blood sample data 
to be used for research. Consent will be requested for 
the use of clinical data, imaging data and blood samples 
collected at baseline (pretreatment) and 24–36 hours 
after hospital presentation. Consent will also be sought 
to store retrieved clots in a subset of patients undergoing 
EVT. To prevent treatment delay, consent will be sought 
after reperfusion therapy is administered. All patients will 
be provided standard acute stroke unit care postreperfu-
sion therapy delivery.
data collection procedures for predictor variables
Prediction models will include clinical, imaging and 
biomarker variables as described below. Candidate clin-
ical and imaging predictors have been identified using 
previously published studies assessing prognostic factors 
for patient outcome following reperfusion therapy for 
acute ischaemic stroke, with an emphasis on factors iden-
tified by multiple independent studies and/or reported 
in systematic reviews. Candidate biomarker variables will 
be identified via mass spectrometry experiments designed 
to identify proteins differing significantly between groups 
of patients with low and high values of ischaemic core 
volume growth from baseline to 24–36 hours follow- up in 
the current study.
Clinical assessments
Standard clinical assessments will be performed at base-
line, at the time of any neurological deterioration and 
24–36 hours poststroke. Measured clinical variables will be 
recognised clinical predictors of stroke outcome including 
prestroke disability (measured using the modified Rankin 
Scale (mRS)31), age, sex, stroke severity (measured using 
the National Institutes of Health Stroke Scale (NIHSS) 
Score), blood glucose, blood pressure, concomitant anti-
thrombotic therapy, OTT time, hospital length of stay, 
EQ5D5 (5- level EuroQol five dimensions questionnaire), 
PROMs (patient reported outcome measures) and 90- day 
mRS. Vascular risk factors and comorbidities such as atrial 
fibrillation will also be measured. Neurological deterio-
ration will be quantified using the NIHSS. Treatment- 
related variables will include—as appropriate—IVT 
therapy type, IVT dose, EVT device type and number of 
passes during EVT.
Stroke mechanism will be ascertained using both the 
TOAST (Trial of Org 10172 in Acute Stroke Treatment) 
criteria32 and the causative classification system.33 34 
Clinical data will be entered in a web- based data repos-
itory for online entry of all clinical variables required to 
comprehensively phenotype reperfusion therapy- treated 
patients.
Radiological assessments
All patients will undergo, as a minimum, baseline non- 
contrast CT, CTP and CTA or multimodal MRI (diffu-
sion, T2, T1, perfusion and MR angiography), as well as 
postreperfusion therapy MRI or CT. The latter is to be 
performed 18–36 hours after reperfusion therapy, but 
accepting occasional logistic limitations, scans up to 
5 days post- therapy will be included if earlier imaging is 
not possible. Patients undergoing EVT will also have a 
preprocedure and postprocedure angiogram recorded. 
This combination of imaging is routinely performed 
during patient work- up for reperfusion therapy in CSCs 
and PSCs in Australia.
We will assess the standard radiological measures 
of hyperdense cerebral artery sign, clot length and 
early infarct signs using the ASPECTS (Alberta stroke 
program early CT score) scoring system,35 as well as 
more advanced pretreatment imaging parameters using 
automated CTP analysis (MISTAR, Apollo Medical 
Imaging, Melbourne, Australia), including volumes of 
ischaemic core, penumbra and severe hypoperfusion, 
and measures of collateral blood flow. CT occlusion will 
be assessed at baseline and on follow- up imaging using 
the thrombolysis in cerebral infarction (TICI) occlusion 
grading system.36
Images will be achieved digitally and uploaded into the 
secure online International Stroke Perfusion Imaging 
Registry (INSPIRE), which has been approved by 
local ethics committees in accordance with the Austra-
lian NHMRC guidelines. Images will undergo central 
‘core laboratory’ analysis and adjudication of any non- 
automated measures will be reviewed by an expert 
neuroradiological panel of three members who will inde-
pendently classify and characterise vessel occlusion and 
any degree of haemorrhagic transformation. Disagree-
ment will be resolved by consensus.
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Blood sample collection and analysis
Blood sample collection
All patients will undergo blood collection for baseline 
and follow- up (24–36 hours) assessment of circulating 
biomarkers. Blood samples will be collected in sodium 
citrate tubes and serum- separator tubes then centrifuged 
at room temperature to produce platelet free plasma and 
serum, which will be aliquoted and frozen at −80°C within 
2.5 hours of initial sample collection.
Blood sample preparation
A single tube containing the patient’s plasma sample will 
be thawed on ice and used for mass spectrometry analysis. 
Subsequently, 10 µL of the sample will be incubated with six 
volumes of ice- cold acetone overnight at −20°C. The tubes 
will be centrifuged at 1400×g for 10 min at 4°C the following 
day to precipitate the proteins. The supernatant will be 
discarded, and the protein pellet air- dried on ice to remove 
any residual acetone. The protein pellet will be dissolved 
in 100 µL of 0.1 M triethylammonium bicarbonate buffer 
(Sigma Aldrich, Australia). The proteins will be incubated 
with 0.05% sodium dodecyl sulphate and 0.005 M tris(2- 
carboxyethyl) phosphine hydrochloride solution (Sigma 
Aldrich, Australia) at 85°C (5 min) and 60°C (30 min) 
for sequential denaturation and reduction. The cysteine 
blocking agent, methyl methanethiosulfonate (Sigma 
Aldrich, Australia) will be added to a final concentration of 
20 mM. Proteolytic digestion will be carried out with trypsin 
(Promega, Australia) for 16 hours at 37°C (1:50 trypsin:pro-
tein by weight). The lipids present in the tryptic peptides 
will be precipitated with 1% formic acid (Sigma Aldrich, 
Australia), followed by centrifugation at 1500×g for 5 min. 
The supernatant will be collected, dried under nitrogen gas 
and dissolved in 0.1% trifluoroacetic acid (Sigma Aldrich, 
Australia). The samples will then be de- salted using POROS 
R3 resin (Thermo Scientific). The resulting peptides will be 
dried, resuspended in 10 µL of 0.1% formic acid and anal-
ysed by mass spectrometry.
Liquid chromatrography–mass spectrometry (LC–MS) and data 
acquisition
The peptide samples will be separated by nano- liquid chro-
matography (nLC) using the NanoElute nLC system (Bruker 
Daltonics, Germany) coupled online to the timsTOF Pro 
mass spectrometer (Bruker Daltonics, Germany). A 1–2 µL 
aliquot of each sample will be loaded onto a 75 µm internal 
diameter capillary column. Columns are prepared in- house 
using Reprosil- pur 120 C18- AQ material (1.9 µm beads, Dr 
Maisch, Germany). The peptides will be separated using 
Buffer A (0.1% formic acid) and Buffer B (90% acetonitrile 
and 0.1% formic acid) at a flow rate of 400 nL/min using a 
60 min gradient. Three technical replicates of each sample 
will be run.
LC–MS data processing
The raw data files from each sample generated on the 
timsTOF Pro mass spectrometer will be processed using 
the software packages PEAKS X (Bioinformatics Solutions) 
and MaxQuant (Max Planck Institute of Biochemistry, 
Germany). The data will be searched against the UniProt 
reference proteome for Homo sapiens with the following 
parameters: Variable modifications—deamidation 
(N/Q), oxidation (M); fixed modification—methylthio 
(C); enzyme—trypsin; missed cleavages—2; search toler-
ance—25 ppm; MS/MS tolerance—0.5 Da. Only proteins 
with a false discovery rate of ≤1% will be reported.
LC–MS data analysis
The  proteinGroups. txt output file from MaxQuant will be 
used for further analysis. Multivariate statistical analysis will 
be performed using the software packages Perseus (Max 
Planck Institute of Biochemistry, Germany) and Metabo-
Analyst (Xia Lab at McGill University). The proteins and 
clusters that differ significantly between patient outcome 
groups will be identified and analysed. The output files 
from PEAKS X will be analysed for relative protein quan-
titative differences between patient groups.
outcome variables
Primary outcome
The primary outcome is good functional outcome at 90 
days poststroke, defined as a score of 0–2 on the mRS.31 
Scores of 0–2 define patients with either no symptoms 
(mRS=0), some symptoms but no significant disability 
(mRS=1) or slight disability but able to manage their own 
affairs without assistance (mRS=2). The complementary 
outcome group will include patients who have either 
moderate disability (mRS=3), moderately severe disability 
(mRS=4), severe disability (mRS=5) or who were dead 
(mRS=6) 90 days poststroke.
Secondary outcomes
Excellent functional outcome will be defined as a score of 
0–1 on the mRS. Poor functional outcome, an indicator 
of treatment futility, will be defined as a score of 4–6 on 
the mRS. Recanalisation at 24 hours after stroke onset will 
be classified using the TICI grading system,36 37 based on 
angiographic appearances of the treated occluded vessel 
and vessel branches. The TICI classification consists of 
five grades (TICI 0, 1, 2a, 2b or 3). Successful recanalisa-
tion will be defined as TICI grades 2b–3 (either complete 
filling of vascular territory although at a slower rate than 
normal or complete perfusion) and compared with TICI 
grades 0–2a (no perfusion, minimal perfusion or partial 
perfusion with less than two- thirds of the vascular terri-
tory visualised). Successful reperfusion will be measured 
as an 80% or greater decrease in the perfusion lesion 
volume from baseline to 24 hours on perfusion imaging 
(CT or MRI).38
Infarct core growth will be defined as the change 
in ischaemic core volume from baseline to follow- up 
(24–36 hours poststroke) imaging, measured using CTP 
or MRI. Change in NIHSS (ΔNIHSS) will be defined 
as the difference in NIHSS from baseline to follow- up 
(24 hours) assessment. In addition to the dichotomous 
classifications of good and poor functional outcome, the 
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90- day mRS will also be treated as an ordinal variable for 
shift analysis of functional outcome.39
sample size
Predictive models will be built using multivariable logistic 
regression, with predictive performance assessed using 
the area under the receiver- operating characteristic curve 
(AUC), also known as the c- statistic. To ensure clinical 
utility, we estimated the sample size necessary to provide 
80% power to detect an AUC of 0.9 that is significantly 
different from a null value of 0.8, for the primary outcome 
(90- day mRS 0–2), in the sample of patients treated with 
rt- PA.
Previous randomised controlled trials of rt- PA in various 
populations have reported response rates of 35%–53.3% 
for the proportion of patients achieving a good functional 
outcome, defined either as 90- day mRS 0–1 or 0–2.2 4–7 
A systematic review including 12 rt- PA trials reported 
1611/3483 (46.3%) patients treated within 6 hour of onset 
achieved mRS 0–2 at final follow- up (primarily reported 
at 90 days).3 Assuming a response rate of 46% for the 
primary outcome in our sample, a sample of 136 patients 
will provide 80% power to detect an AUC of 0.9 at signif-
icance 0.05.40 A sample of 172 patients will provide 90% 
power assuming the same parameter values. The target 
size of the entire sample is 400, of which approximately 
50% are anticipated to have been treated with rt- PA only. 
The target sample will thus provide adequate power for 
predictive model development for the primary outcome 
and population of interest.
statistical analysis methods
To address the key objectives of the study, predictive models 
will be developed for primary and secondary outcomes in 
patients treated with rt- PA only. As exploratory analyses, 
predictive models will subsequently be developed for the 
same outcomes in patient subgroups receiving: (1) any 
intravenous thrombolytic (rt- PA or TNK (Tenecteplase)); 
(2) EVT alone or (3) IVT followed by EVT. Results from 
exploratory analyses will be reported separately. Data 
management and statistical analyses will be performed 
using SAS v9.4 software and Stata v15 software.
Model derivation and validation
Due to the modest sample size, a variable selection and 
shrinkage approach will be used to select predictor vari-
ables for inclusion in multivariable models. This helps to 
develop predictive models that are parsimonious while 
retaining the most important prognostic variables.41 42 
Models will be simplified using the stepdown procedure 
described by Ambler et al.41 When some predictors are 
only weakly associated with the outcome, this method 
typically produces simplified models with similar or 
better prognostic performance than the full model, 
while retaining good operating characteristics. Model 
selection will be performed using Akaike’s information 
criterion and by assessing model discrimination and 
calibration. Continuous predictors will be retained in 
continuous form to maximise power,43 with fractional 
polynomials used to model non- linear relationships.44 
Clinically relevant interactions (eg, involving OTT time 
and neuroimaging variables) will also be tested for 
inclusion.
The primary estimation model will be a generalised 
linear model with a binomial response distribution and 
logit link (logistic regression), with favourable clin-
ical outcome (90- day mRS 0–2) as the response vari-
able. Model calibration will be assessed by comparing 
observed and expected events by deciles of predicted 
probability.45 Test error will be estimated using 10- fold 
cross validation. For secondary outcomes, models will 
be estimated using generalised linear models with a 
response distribution and link function as appropriate 
for the specified binary, continuous and ordered cate-
gorical responses. For all outcomes, model assumptions 
will be checked using standard diagnostic measures 
and plots, including plots of residuals and fitted values. 
The impact of influential observations or collinearity 
on parameter estimates will be assessed, to increase 
external validity of reported models.
External validation of clinical and radiological predic-
tors will be performed using the INSPIRE.46 External vali-
dation of identified blood biomarkers will be undertaken 
in collaboration with colleagues from the International 
Stroke Genetics Consortium (https:// strokegenetics. 
org/).
Missing data
Complete case analyses will be performed under a 
missing completely at random assumption. To supple-
ment complete case analyses, missing data will be multiply 
imputed under a missing at random assumption to assess 
robustness of results to different presumed missing data 
mechanisms. Imputation models will include variables 
included in predictive models and auxiliary variables 
associated either with observed values of outcome and 
predictor variables, or the missing data mechanism. 
Parameter estimates obtained using multiple imputed 
data will be combined using Rubin’s rules.47
Model performance
For the primary estimation model, the key measure 
of predictive performance will be the c- statistic. For a 
logistic regression model, the c- statistic (equivalent to the 
area under the receiver operator characteristic curve) 
is the probability that a randomly selected patient who 
experienced the event of interest had a higher predicted 
probability than a randomly selected patient who did not 
experience the event. Bootstrap resampling will be used 
to estimate the c- statistic and its 95% CI, to adjust for 
optimism and internally validate the model. Additional 
measures of predictive performance to be reported as 
appropriate for primary and secondary outcomes will 
include R2, pseudo R248 and Brier Score.49
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Patient and public involvement
Patients and the public will not be involved in this 
research, since there were no time or funds allocated for 
such involvement.
Ethics and dissemination
Patients, or their relatives when patients could not 
consent, provided written informed consent to partic-
ipate in the study. This study received approval from 
the Hunter New England Local Health District Human 
Research Ethics Committee (reference 14/10/15/4.02). 
The INSPIRE was approved by the Hunter New England 
Local Health District Human Research Ethics Committee. 
Data management will be performed by TL and EH. All 
acquired data will be de- identified, stored electronically 
and password protected. Data quality checks will be 
performed by TL, AB and EH. The final dataset will be 
curated by EH and access will be at the discretion of study 
investigators.
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